Nexstim Plc · OMXHEX:NXTMH
Nexstim — BioCapital Europe 2015
16 slides from Nexstim's conference presentation, Mar 26, 2015
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Janne Huhtala | CEO | Nexstim 26 March 2015 @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj FORWARD-LOOKING STATEMENTS (“Nexstim” or the “Company”). In connection with any presentation or review of this This document may contain forward-looking statements that reflect the Company’s c
Slide 3: Nexstim at a glance
Nexstim at a glance ● Finnish Medtech in Neuromodulation ● Targeting Unmet Need in Stroke Motor Rehabilitation ● Proprietary e-Field based Navigation as Differentiator ● Established in 2000 ● 34 employees 3
Slide 4: Nexstim at a glance
Nexstim at a glance ● Listed in Nasdaq First North Helsinki & Stockholm since Nov 2014 ● Strong Investor Support for Current Development Phase ● Clear Execution Strategy and Growth Opportunity Strongly positioned with IPR and Clinical Evidence to Non- invasive Neuromodulation in Therapeutic Applicat
Slide 5: Nexstim – Targeting a paradigm shift in stroke rehabilitation
Nexstim – Targeting a paradigm shift in stroke rehabilitation Nexstim’s Nexstim’sNavigated NavigatedBrain BrainTherapy® Therapy®solution (NBT) Targeting Targetingaablockbuster blockbustermarket… market for stroke solution rehabilitation for stroke rehabilitation (market for post-acute stroke treatme
Slide 6: Technology platform applied in stroke and brain surgery
Technology platform applied in stroke and brain surgery Novel technology Two products Main uses Status Navigation technology to Stroke rehabilitation –CE marked deliver accurate magnetic Navigated Precise localisation of the –Positive Phase II data pulses to stimulate the Brain correct motor center
Slide 7: NBT® for stroke rehabilitation – How it works
NBT® for stroke rehabilitation – How it works Magnetic field • 30 000 tesla/s Coil • Peak 1-2 tesla current Skull Electric field 100 V/m Cortex Neuronal activation Stimulation up to: • 4 cm deep • 250% average Motor Threshold Using a patient’s own MRI scan as a guide, Nexstim Because the injured sid
Slide 8: Efficacy demonstrated in Phase II trial
Efficacy demonstrated in Phase II trial Change in upper extremity Fugl-Meyer score from baseline Trial outcome: Absolute average improvement of 20 13.8 Fugl-Meyer scores 15 P<0.05 = difference of "holding an object" and "buttoning a shirt" 84% responder rate (above "MCID" for NBT® group) 10 Differen
Slide 9: Nexstim's unique technology provides distinct benefits
Nexstim’s unique technology provides distinct benefits Integration of TMS and navigation Several distinct benefits Enhanced limb move ● TMS-navigation integration: ● Improved accuracy: Accurate ● Substantially Nexstim combines non-invasive localisation of the target muscle improved hand transcranial
Slide 10: IP position
IP position 62 granted patents 69 pending patents Right to software: Nexstim owns rights to its NBT® and NBS Systems’ software developed in-house. Creating hurdles for competitors: e.g. by seeking patent protection on different parts of the products and making it more difficult for potential competi
Slide 11: Phase III trials - Laying the groundwork for commercialisation
Phase III trials - Laying the groundwork for commercialisation Study in brief Study goals Conducted at 12 top US rehab sites ● Establish clinical efficacy ● Document Rehabilitation Institute of Chicago (central site) of NBT® in upper-limb effects/efficacy of TIRR Memorial Hermann Hospital (Houston)
Slide 12: Status of Clinical Development
Status of Clinical Development ● The clinical Phase III multi-center trial is progressing according to plans. The next interim analysis milestones are estimated to be reached Q3 2015 and Q1 2016 and the clinical evidence is assumed to be ready by the end of 2016 ● In addition, chronic neuropathic pa
Slide 13: Highlights in Stroke Rehabilitation (NBT®)
Highlights in Stroke Rehabilitation (NBT®) – 2.1m strokes each year in the US and Europe Huge unmet need – Stroke is the leading cause of long-term disability in Western world – While current standard treatment of physical/occupational therapy is not very Few effective alternatives effective, $8.5bn
Slide 14: Financials
Financials EUR in thousands H2 2014 H2 2013 FY 2014 FY 2013 6 months 6 months 12 months 12 months Net sales 1,796.5 1,371.7 2,210.4 1,871.0 Personnel expenses -2,018.3 -1,492.5 -3,660.2 -3,043.4 Depreciation and amortisation -252.1 -96.0 -377.4 -237.7 Other operating expenses -3,826.2 -1,403.8 -5,49
Slide 15: Summary and Outlook
Summary and Outlook ● World-leading medical technology and software with game changing potential in stroke rehabilitation ● Good progress since IPO – business on track ● Based on its business forecast and sensitivity analysis the company expects its net sales from the sale of NBS Systems (Pre-Surgic
Slide 16: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation @NexstimOyj